biolitec AG achieved consolidated revenue of Euro 35.4 million for the fiscal year 2007/2008 -expectation of sales growth to resume in this fiscal year

R&D expenditures with Euro 5.1 million remained at a high level –
urology and aesthetic laser therapy remain growth markets – strongest
urology laser worldwide already in use in Germany

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

companies/finances/shares/stock market/Annual Report

Jena (euro adhoc) - Jena, September 30, 2008 - biolitec AG, Jena,
listed in the Prime Standard of the Frankfurt stock exchange (ISIN
DE0005213409) posted a consolidated revenue of Euro 35.4 million for
the fiscal year 2007/2008. Mainly contributing to this were the
business segments urology laser, vein treatment and laser
liposuction.

The revenue was 9% lower than in the prior year due to the
unfavourable investment climate in the USA, its impact on the
investment cycle and the unfavourable dollar exchange rate. In the
USA biolitec AG is market leader in the sector of ambulant therapy of
the benign prostate hyperplasia (BPH). More than 600 US urologists
already have applied LIFE™ laser therapy, about 200 as in-office
treatment. At the 2008 American Urological Association´s (AUA)
National Scientific Meeting in Orlando/Florida US urologists were
keen on the gentle in-office treatment with biolitec´s laser Evolve™
150 and the short treatment time.

R&D expenditures for the fiscal year 2007/2008 of Euro 5.1 million
(14% of sales) remained at a high level to ensure the groups long
term growth and profitability. Net income amounted to about Euro 2
million despite the continuous high R&D investments as well as the
decline in sales. The gross profit amounted to about Euro 24 million
and EBIT amounted to Euro 1.4 million.

For example biolitec has just revolutionized endovenous laser
treatment for varicose veins by the application of the new,
innovative laser fiber ELVeS® RADIAL, which emits the light radially.

The revenue posted by the laser segment of Euro 12.1 million was
lower than in the prior year mainly due to the market decline in the
USA. The fiber optics and laser probes segment contributed to about
Euro 22 million to the group´s total revenue. Mainstays of sales are
the LIFE™ BPH laser treatment and the Endoluminal Laser Treatment of
Veins (ELVeS™).

The urology laser Evolve™ 150 is rising further in the estimation of
physicians and the number of LIFE™ laser treatment centres is
increasing continuously. In Germany the outpatient treatment of BPH
with the Evolve™ laser is gaining ground. The biolitec AG has
recently introduced the first 300 watt urology laser to the German
market.

biolitec´s major revenues were again generated in Europe and North
America. With Euro 14.7 million, sales in North America were 22%
lower than previous year´s sales contributing 42% of total sales.
European sales amounted to Euro 17.9 million (previous year 17.8%).

Dr. Wolfgang Neuberger, CEO of biolitec AG: "We proceed on the
assumption that the demand on gentle urology therapies as well as
treatments in the field of aesthetics will further increase and the
market caution will decrease. Due to our excellent market position in
Europe and North America we expect an increase in turnover and profit
in the current fiscal year even driven by the expenditures of
transacted research and development."

About biolitec biolitec is the only supplier for photodynamic therapy
worldwide that offers all relevant core competencies -
photosensitizers, lasers and optical fibers. Besides minimal invasive
laser treatments and the oncology business biolitec has successfully
developed competencies in the field of aesthetics. biolitec is listed
in the Prime Standard under ISIN DE0005213409. For more information:
www.biolitec.com.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: BioLitec AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Press contact

Jörn Gleisner

Telefon : +49 (0) 69 / 959083-20

Telefax : +49 (0) 69 / 959083-99

E-Mail: joern.gleisner@biolitec.com

Branche: Pharmaceuticals
ISIN: DE0005213409
WKN: 521340
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade